Ftse Mib
34.067,28
0,70%
DAX
20.232,14
0,98%
S&P 500
6.074,31
0,40%
NASDAQ
19.649,68
0,87%
Bitcoin
96.338,55
0,38%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Pieris Pharmaceuticals Inc (PIRS) Pieris Pharmaceuticals Inc (PIRS) Notizie

Pieris Pharmaceuticals Inc

PIRS
16,2198
0,1198 (0,74%)
Ultimo aggiornamento: 19:28:46
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
03/12/202414:30EDGAR2Form 425 - Prospectuses and communications, business..
03/12/202414:30EDGAR2Form 8-K - Current report
18/11/202422:16EDGAR2Form 3 - Initial statement of beneficial ownership of..
14/11/202415:07EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
13/11/202422:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202415:01EDGAR2Form 425 - Prospectuses and communications, business..
07/11/202414:30GLOBEPalvella Therapeutics Announces First Patient Dosed in SELVA..
06/11/202423:01EDGAR2Form DEF 14A - Other definitive proxy statements
17/10/202414:00EDGAR2Form 425 - Prospectuses and communications, business..
17/10/202413:30GLOBEPalvella Therapeutics Appoints Matthew E. Korenberg as Chief..
15/10/202414:00EDGAR2Form 425 - Prospectuses and communications, business..
03/10/202414:00EDGAR2Form 425 - Prospectuses and communications, business..
03/10/202414:00EDGAR2Form 8-K - Current report
14/8/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/8/202400:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202422:17EDGAR2Form 425 - Prospectuses and communications, business..
08/8/202422:17EDGAR2Form 8-K - Current report
07/8/202420:16EDGAR2Form SCHEDULE 13G - Statement of Beneficial Ownership by..
01/8/202414:00EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
24/7/202423:03PRNUSALERT: Rowley Law PLLC is Investigating Proposed Acquisition..
24/7/202412:40EDGAR2Form 425 - Prospectuses and communications, business..
24/7/202412:40EDGAR2Form 8-K - Current report
15/5/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202414:00EDGAR2Form 8-K - Current report
14/2/202422:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202419:12EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202415:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
02/2/202415:59EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
21/12/202322:30EDGAR2Form 8-K - Current report
Apertura: 16,20 Min: 16,20 Max: 16,25
Chiusura: 16,10

La tua Cronologia

NASDAQ
PIRS
Pieris Pharmaceuticals
NASDAQ
PDSB
PDS Biotechnology
FX
USDBYN
US Dollar vs BYN
LSE
XMWX
X World Ex Us
NASDAQ
IRTC
iRhythm Technologies
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network